Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 study

Li, JX; Hui, AM; Zhang, X; Yang, YM; Tang, R; Ye, HY; Ji, RR; Lin, M; Zhu, ZK; Tureci, O; Lagkadinou, E; Jia, SY; Pan, HX; Peng, FZ; Ma, ZL; Wu, ZG; Guo, XL; Shi, YF; Muik, A; Sahin, U; Zhu, L; Zhu, FC

Zhu, FC (corresponding author), Jiangsu Prov Ctr Dis Control & Prevent, NHC Key Lab Enter Pathogen Microbiol, Nanjing, Peoples R China.; Hui, AM (corresponding author), Fosun Pharma, Boston, MA 01862 USA.; Zhu, L (corresponding author), Taizhou Peoples Hosp, Taizhou, Peoples R China.; Zhu, FC (corresponding author), Nanjing Med Univ, Ctr Global Hlth, Nanjing, Peoples R China.

NATURE MEDICINE, 2021; 27 (6): 1062

Abstract

An effective vaccine is needed to end the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. Here, we assess the preliminary safet......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索